BioView and Abbott to Collaborate on Automated FISH Scanning for Vysis ALK Probe Kit

  BioView and Abbott to Collaborate on Automated FISH Scanning for Vysis ALK
                                  Probe Kit

PR Newswire

REHOVOT, Israel, November 28, 2012

REHOVOT, Israel, November 28, 2012 /PRNewswire/ --

BioView Ltd. (TASE: BIOV), announced today that they have entered into an
agreement with Abbott to collaborate on the development of an automated
scanning solution to detect rearrangements of the anaplastic lymphoma kinase
(ALK) gene in patients with advanced non-small cell lung cancer (NSCLC).

Under terms of the agreement BioView will perform the appropriate studies to
obtain regulatory approval for its Duet Automated Scanner to include an
indication for automated imaging and analysis of Abbott's Vysis ALK Break
Apart FISH Probe Kit.

Abbott plans to utilize the BioView product in its own clinical trials for
future regulatory approval for end-to-end automation of the preparation,
scanning and scoring of formalin-fixed paraffin-embedded (FFPE) non-small cell
lung cancer tissue specimens, probed with the ALK Kit.

After receiving regulatory approvals, the parties plan to co-promote the
BioView product worldwide, in compliance with applicable regulatory rules.

In addition, the Companies are exploring the possibility of incorporating
BioView Scanning Automation to further automate Abbott's future FISH assay

The Duet™ System is intended for in-vitro diagnostic use as an aiding tool to
the pathologist in the detection, classification and counting of cells of
interest based on color, intensity, size, pattern, and shape. The Duet^[^TM^]
has FDA clearances for the automated imaging and analysis of:

  oHematopoietic cells stained by Giemsa stain, Immunohistochemistry or ISH
    (with bright field and fluorescent) prepared from cell suspension
  oAmniotic cells stained by FISH (using direct labeled DNA probes for
    chromosomes X, Y, 13, 18 and 21)
  oCells in urine specimens, stained by FISH using the Vysis UroVysion^[^TM^]
    Bladder Cancer Recurrence Kit
  oFFPE breast tissue specimens probed by the Vysis® PathVysionTM HER-2 DNA
    Probe Kit.

About BioView Ltd.

Established in 2000, and led by an expert team of biologists, software
engineers and physicists, BioView develops, manufactures and supplies cell
imaging equipment, biological kits and software to medical institutes and
universities. BioView is a publicly traded company on the Israeli Stock
exchange, and currently has strategic collaborations underway with
international scientific leaders and institutions. For more information about
the BioView technology, and press related issues, please contact or visit our website at

Contact Information:
Dr. Alan Schwebel President and CEO
Tel: +972-8-936-6868

SOURCE BioView Ltd
Press spacebar to pause and continue. Press esc to stop.